Key Data Presentations (Pfizer-Sponsored and Collaborative Research Studies) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018

The embargo on all data will lift on Wednesday, May 16, at 5:00 p.m. EDT.

Avelumab:


(Abstract 9008) Avelumab (anti-PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC: Phase Ib Results from the JAVELIN Lung 101. Shaw A. Friday, June 1. Session Type: Oral. Presentation Time: 4:30 p.m. – 6:00 p.m. CDT. Location: Hall D1.

(Abstract 9090) Avelumab (anti-PD-L1) in Patients with Platinum-Treated Advanced NSCLC: 2.5-Year Follow-Up from the JAVELIN Solid Tumor Trial. Rajan A. Sunday, June 3. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 413.


(Abstract 3057) Association of Efficacy and Adverse Events of Special Interest of Avelumab in the JAVELIN Solid Tumor and JAVELIN Merkel 200 Trials. Kelly K. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 271.

(Abstract 4544) SPEAR-Bladder (Study Informing Treatment Pathway Decision in Bladder Cancer): First-Through Third-Line Time to Treatment Failure in the US. Doshi G. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 370.

Bosutinib:

(Abstract 7002) Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: 24-Month Follow-Up. Cortes JE. Saturday, June 2. Session Type: Oral. Presentation Time: 3:00 p.m. – 6:00 p.m. CDT. Location: E450.

(Abstract 7062) Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors (TKIs) in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Leukemia: Phase III Study Update. Gambacorti-Passerini C. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 122.
Crizotinib:

(Abstract 9062) Crizotinib in Patients (Pts) with MET-Amplified Non-Small Cell Lung Cancer (NSCLC): Updated Safety and Efficacy Findings from a Phase I Trial. Camidge DR. Sunday, June 3. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 385.

Dacomitinib:

(Abstract 9004) Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced NSCLC (ARCHER 1050): Final Overall Survival Analysis. Mok T. Monday, June 4. Session Type: Oral. Presentation Time: 3:00 p.m. – 6:00 p.m. CDT. Location: Hall B1.

Enzalutamide:

(Abstract 5043) Association Between Health-Related Quality of Life (HRQoL) and Clinical Outcomes in Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC): Results from the PROSPER Study. Attard G. Saturday, June 2. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: 270.

Enzalutamide:

(Abstract 5010) Health-Related Quality of Life (HRQoL) Deterioration and Pain Progression in Men with Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC): Results from the PROSPER Study. Attard G. Saturday, June 2. Session Type: Poster Discussion Session. Presentation Time: 4:45 p.m. – 6:00 p.m. CDT. Location: S406. Poster Board: 237.

Glasdegib:

(Abstract TPS7073) Phase III, Randomized, Placebo-Controlled Trials Evaluating Glasdegib in Combination with Intensive or Nonintensive Chemotherapy in Patients with Untreated Acute Myeloid Leukemia. Cortes JE. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 133a.

Inotuzumab:

(Abstract 7028) Inotuzumab Ozogamicin (InO) Treatment in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Analysis from INO-VATE by Bone Marrow Blast Percentage (BMB%). Advani A. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 88.

Inotuzumab:

(Abstract 7029) Extensive Safety Profile of Inotuzumab Ozogamicin (InO) in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Patients Enrolled in the Phase III INO-VATE Trial. Cassaday R. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 89.

Inotuzumab:

(Abstract 7030) Outcomes with Inotuzumab Ozogamicin (InO) in Patients with Philadelphia Chromosome-Positive (Ph+) Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Stock W. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 90.
(Abstract 7013) Impact of Minimal Residual Disease (MRD) Status in Clinical Outcomes of Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (InO) in the Phase III INO-VATE Trial. Jabbour E. Monday, June 4. Session Type: Poster Discussion Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion Time: 11:30 a.m. – 12:45 p.m. Location: E450. Poster Board: 73.

Lorlatinib:


Palbociclib:

(Abstract 1001) Genetic Landscape of Resistance to CDK4/6 Inhibition in Circulating Tumor DNA (ctDNA) Analysis of the PALOMA3 Trial of Palbociclib and Fulvestrant Versus Placebo and Fulvestrant. Turner N. Sunday, June 3. Session Type: Oral. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall D2.

(Abstract 6008) Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC). Adkins D. Sunday, June 3. Session Type: Oral. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: E451.

(Abstract 1023) Treatment Effect of Palbociclib (PAL) Plus Endocrine Therapy (ET) by Prognostic and Intrinsic Subtype: A Joint Analysis of PALOMA2 and PALOMA3. Finn RS. Saturday, June 2. Session Type: Poster Discussion Session. Presentation Time: 1:15 p.m. – 2:30 p.m. CDT. Location: Hall D1. Poster Board: 104.

(Abstract 1060) Hematologic Adverse Events Following Palbociclib (PAL) Dose Reduction in Patients (Pts) with Hormone Receptor—Positive (HR+)/Human Epidermal Growth Factor Receptor-2—Negative (HER2—) Advanced Breast Cancer (ABC): Pooled Analysis from Randomized Phase II and III Studies. Verma S. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 141.

Sunitinib:

(Abstract 4565) Disease-Free Survival in Patients at Highest Risk of Recurrent Renal Cell Carcinoma in S-TRAC. Ravaud A. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 391.


Talazoparib:

(Abstract TPS5091) TALAPRO-2: A 2-Part, Placebo-Controlled Phase III Study of Talazoparib (TALA) With Background Enzalutamide (ENZA) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) With DNA
Damage Repair Deficiencies. Agarwal NR. Saturday, June 2. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: 315b

(Abstract 1070) Analysis of Germline BRCA1/2 Mutated (gBRCAmut) Hormone Receptor-Positive (HR+) and Triple Negative Breast Cancer (TNBC) Treated with Talazoparib (TALA). Eiermann W. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 151.

(Abstract 1069) EMBRACA: Efficacy Outcomes in Clinically Relevant Subgroups Comparing Talazoparib (TALA), an Oral Poly ADP Ribose Polymerase (PARP) Inhibitor, to Physician's Choice of Therapy (PCT) in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. Rugo HS. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 150.

(Abstract 2548) NCI9782: A Phase I Study of Talazoparib in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors. Turk A. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 374.

Early-Pipeline Assets:

Anti-PTK7 (PF-06647020):

(Abstract 5565) PF-06647020 (PF-7020), an Antibody-Drug Conjugate (ADC) Targeting Protein Tyrosine Kinase 7 (PTK7), in Patients (Pts) with Advanced Solid Tumors: Results of a Phase I Dose Escalation and Expansion Study. Sachdev JC. Monday, June 4. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: 292.

(Abstract 2574) Clinical Pharmacology Assessment of PF-06647020 (PF-7020), an Antibody-Drug Conjugate (ADC) Targeting Protein Tyrosine Kinase 7 (PTK7), in Adult Patients (Pts) with Advanced Solid Tumors. Xuan D. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 400.

Gedatolisib:

(Abstract 1040) Phase Ib Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy (ET) in Women with Estrogen Receptor (ER) Positive (+) Metastatic Breast Cancer (MBC) (B2151009). Forero A. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 121.

Biosimilars:


###